Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
-
Solid Biosciences to Participate at Upcoming Investor Conferences
-
Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit
-
Solid Biosciences Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
-
Solid Biosciences (SLDB) Prices 21.74M Share Common Offering at $5.75/Sh
-
Solid Biosciences Announces Pricing of Public Offering of Common Stock
-
Solid Biosciences (SLDB) to Offer $85M in Common Stock
-
Solid Biosciences Announces Proposed Public Offering of Common Stock
-
Solid Biosciences (SLDB) PT Raised to $20 at Chardan Capital Markets
-
Buy Solid Biosciences (SLDB) on Weakness - Chardan Capital
-
Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 4th Annual Genetic Medicines Conference
-
Solid Biosciences (SLDB) PT Raised to $12.50 at Chardan Capital Markets
-
Solid Biosciences to Participate in the Chardan 3rd Annual Genetic Medicines Conference
-
Solid Biosciences (SLDB) PT Raised to $15 at Chardan Capital Markets
-
Chardan Capital Markets Upgrades Solid Biosciences (SLDB) to Buy
-
Chardan Capital Markets Downgrades Solid Biosciences (SLDB) to Neutral
-
Solid Biosciences (SLDB) PT Lowered to $15 at Chardan Capital Markets
-
Solid Biosciences to Present at the Chardan Genetic Medicines Conference
-
Solid Biosciences (SLDB) PT Raised to $60 at Chardan Capital Markets
-
Solid Biosciences (SLDB): Removal of Clinical Hold a 'Clear Positive' - Chardan Capital Markets
-
Chardan Capital Markets Starts Solid Biosciences (SLDB) at Buy
-
Solid Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Overallotment Option
-
Solid Biosciences (SLDB) IPO Opens Up 59%
-
Solid Biosciences Inc. (SLDB) Prices 7.81M Share IPO Offering at $16/Sh
-
Solid Biosciences Announces Pricing of Initial Public Offering
-
Solid Biosciences Files $100M NASDAQ IPO; Plans to List Under Ticker 'SLDB'

